Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

The stock's fall snapped a two-day winning streak.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...